Proactive Investors - Run By Investors For Investors

Orgenesis CEO Vered Caplan says it's a 'very exciting time' for cell therapy in Fox interview

'I think it’s very impressive how globally regulatory agencies have taken on the challenge of finding a way to get these drugs to patients,' Caplan said in an interview on 'Mornings with Maria'
scientists in a lab
Orgenesis is a developer and manufacturer of advanced cell therapies

Vered Caplan, the CEO of Orgenesis Inc (NASDAQ:ORGS), a developer of advanced cell therapies, said her business is undergoing a “very exciting time” thanks to regulators working together to get cell therapies to patients, according to a Fox Business Network interview on the program “Mornings with Maria” held on Thursday.

“I think it’s very impressive how globally regulatory agencies have taken on the challenge of finding a way to get these drugs to patients,” Caplan said on the program.

"It’s exciting to see how scientists and regulatory people around the world are working together. Even a bone marrow transplantation is a cell therapy,” added Caplan.

READ: Orgenesis seals pact with Ben-Gurion University to develop dissolvable carriers for cell culturing

Developing cell therapies offers up challenges as it’s impossible to devise them as you would a plastic or a chemical material. “Making these drugs, making these products is the biggest engineering challenge so to speak,” Caplan said on Fox. “This is living material. These are the cells of our body.”

A developer and manufacturer of advanced cell therapies, Orgenesis is building a unique and fundamental base platform of know-how and expertise for a multitude of cell types and for the regenerative medicine industry. Based in Germantown, Maryland, the company conducts much of its research in Belgium and has also recently opened an operation in Korea. 

Orgenesis shares held steady at $5.17 in Thursday’s morning trading session.


View full ORGS profile View Profile

Orgenesis Timeline

Related Articles

November 30 2018
It’s been a tricky period for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
A paper plane about to be launched with the help of surgical scissors
November 13 2018
The voluntarily-suspended company is progressing an ongoing recapitalisation plan.
February 22 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use